Nobel Biocare is a Swiss-heritage premium brand owned by Envista; Osstem is a South Korean brand and one of the most widely placed implants in the world by volume. The price gap between them is real, but volume and price are market facts, and neither settles the clinical question, which studies answer rather than sales figures.
Side by side
Rows appear only where at least one side has data. Where a value is not verified we say
so rather than leaving it blank.
Nobelpharma was founded in Gothenburg, Sweden in 1981 and renamed Nobel Biocare in 1996; the underlying work is Per-Ingvar Brånemark’s, who placed the first titanium dental implant in 1965Verified spec[4]
Owned by Envista Holdings. Danaher Corporation completed its acquisition of Nobel Biocare Holding AG on 11 December 2014, taking about 97% of the shares and moving to delist the company from the SIX Swiss Exchange; Envista was formed inside Danaher in 2018 and separated in 2019, taking Nobel Biocare with itVerified spec[5][1][3]Nobel Biocare’s own timeline dates the Danaher acquisition to 2015; Danaher’s completion release is dated 11 December 2014, with the squeeze-out and delisting following in the first quarter of 2015. The two dates describe different stages of the same transaction.
Nobelpharma was founded in Gothenburg, Sweden in 1981 and renamed Nobel Biocare in 1996; the underlying work is Per-Ingvar Brånemark’s, who placed the first titanium dental implant in 1965Verified spec[4]
Owned by Envista Holdings. Danaher Corporation completed its acquisition of Nobel Biocare Holding AG on 11 December 2014, taking about 97% of the shares and moving to delist the company from the SIX Swiss Exchange; Envista was formed inside Danaher in 2018 and separated in 2019, taking Nobel Biocare with itVerified spec[5][1][3]Nobel Biocare’s own timeline dates the Danaher acquisition to 2015; Danaher’s completion release is dated 11 December 2014, with the squeeze-out and delisting following in the first quarter of 2015. The two dates describe different stages of the same transaction.
Sold through subsidiaries across more than 90 countriesManufacturer-reported[7]
The biggest differences
Nobel Biocare grew out of Brånemark's osseointegration work and the company Nobelpharma, founded in Gothenburg in 1981 and renamed in 1996, and is now owned by Envista. Osstem Implant of South Korea, founded in 1997, is a private company since its 2023 KOSDAQ delisting, and its TS line is its flagship. UK patients most often meet Osstem in quotes for treatment in Turkey, Hungary or Korea, and Nobel Biocare across both domestic and overseas treatment.
Prosthetic ecosystem
Both brands run their own connection families, and neither takes the other's components. Within Osstem the TS line shares one connection across TS II, III and IV; within Nobel Biocare the internal conical connection spans the current implants. Osstem also trades as Hiossen in the United States — the same manufacturer under a different name — which is worth knowing when tracing a component supply chain.
Geographic availability and serviceability
Osstem states it sells through subsidiaries across more than 90 countries and is among the highest-volume implant brands globally, so its components are widely obtainable. Nobel Biocare is a long-established premium brand with international distribution. For a UK patient treated abroad with either, the practical question is whether a local dentist can obtain the matching parts later, which turns on identifying the exact system and connection.
Cost considerations
Nobel Biocare is a premium brand; Osstem is positioned in the value segment. The difference will be visible in any quote. It is not a quality ranking: Osstem's very high placement volume is a reasonable proxy for parts being obtainable, but volume is a commercial measure and says nothing about outcomes, which are a separate question answered by clinical evidence.
What may influence clinical selection
The honest guidance is the same as for any premium-versus-value pairing: price positioning does not decide clinical suitability. What decides a good result is the bone, the plan, the restoration and the clinician's fluency with the specific system, plus the serviceability of components where the patient lives. A brand name alone, at either end of the price range, is not enough to plan or to maintain treatment.
So which is better?
Neither is universally better, and any page telling you otherwise is selling something.
These are different designs with different trade-offs, and the right choice depends on the
bone available, the position in the mouth, the planned restoration, and what the treating
clinician is equipped and experienced to place and to service years from now.
That last point is easy to overlook and matters more than most specification
differences: components need to remain obtainable for as long as the implant is in place.
Regulatory record
US FDA 510(k) clearances held by each side, retrieved from the FDA's own database.
Nobel Biocare
6
FDA 510(k) clearances
1991 – 2026
Filed by Nobel Biocare AB
Osstem
5
FDA 510(k) clearances
2016 – 2023
Filed by Osstem Implant Co., Ltd.
A clearance count is not a quality ranking, and the
larger number is not the better implant. A brand with more clearances usually
has a longer history or a broader component range. FDA "clearance" also is not FDA
"approval" — it means the device was accepted as substantially equivalent to one already
on the market, generally without a clinical trial. A blank here means we could not match
a filing with confidence, not that the brand lacks authorisation.
What these actually mean →
Sources
Numbers match the citations beside each claim above.
